Skip to main content
FQHC Talent

Cookie notice

Allow detailed analytics to improve the site?It's from us, Google and Vercel, and stays off until you accept. If you're signed in, it can link your visits across devices. Declining doesn't limit what you can use. Details & privacy.

Back to the news
Lobbying & Advocacy

AHA files opposition to HRSA's 340B rebate model

Federal

Issue

340B drug pricingIn court

Next: · Amgen to request 340B visit claims data starting November 15

The American Hospital Association filed formal opposition to HRSA's 340B rebate model on April 20, 2026, the comment deadline, calling any rebate mechanism flawed. AHA warned the shift would cost billions and hurt access for millions.

It joins NACHC and PhRMA in opposing the pilot while manufacturer rebate plans keep starting.

Sources for this story

American Hospital Association

Part of

Sources for your board packet

This story's source plus 4 related stories and their sources, ready to print for your team or board.

Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.

More in Lobbying & Advocacy

Cite this analysis

FQHC Talent. (2026, April 20). AHA files opposition to HRSA's 340B rebate model. Source: American Hospital Association. Retrieved November 11, 2026, from https://www.fqhctalent.com/intel/aha-hrsa-340b-rebate-opposition-april-20-2026